Literature DB >> 27048639

Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.

Christina A Sutherland1, David P Nicolau2.   

Abstract

Herein, we report the development and validation of an HPLC method to analyze ceftolozane and tazobactam simultaneously in human plasma, human serum, swine serum and saline matrixes. A reversed-phase column was used with a UV detector set at 260 nm and switched to 218 nm. The mobile phase consisted of methanol and sodium phosphate buffer at a flow rate of 1.1 mL/min. Cefepime was used as the internal standard. The standard curves were linear over a range of 0.4-50 μg/mL. This methodology represents a simple, reproducible approach to the determination of drug concentrations with sufficient accuracy and precision for pharmacokinetic studies undertaken with this recently FDA-approved antimicrobial therapy.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27048639     DOI: 10.1093/chromsci/bmw047

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  13 in total

1.  Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.

Authors:  Ana Motos; Joseph L Kuti; Gianluigi Li Bassi; Antoni Torres; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  In vitro blood culture bottle inoculation of whole blood with clinically relevant antibiotic concentrations: a word of caution.

Authors:  M Grupper; J L Kuti; D P Nicolau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-28       Impact factor: 3.267

3.  Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.

Authors:  Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

4.  Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Authors:  Marguerite L Monogue; Rebecca S Pettit; Marianne Muhlebach; Jeffrey J Cies; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.

Authors:  María Milagro Montero; Sandra Domene-Ochoa; Carla López-Causapé; Inmaculada López-Montesinos; Sonia Luque; Luisa Sorlí; Núria Campillo; Eduardo Padilla; Núria Prim; Lorena Ferrer Alapont; Santiago Grau; Antonio Oliver; Juan P Horcajada
Journal:  Microbiol Spectr       Date:  2022-06-13

6.  Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.

Authors:  Marguerite L Monogue; Sean M Stainton; Arlinda Baummer-Carr; Ashley K Shepard; James F Nugent; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

7.  Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model.

Authors:  Veronica Rico Caballero; Safa Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

8.  Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model.

Authors:  María Montero; Sandra Domene Ochoa; Carla López-Causapé; Brian VanScoy; Sonia Luque; Luisa Sorlí; Núria Campillo; Ariadna Angulo-Brunet; Eduardo Padilla; Núria Prim; Virginia Pomar; Alba Rivera; Santiago Grau; Paul G Ambrose; Antonio Oliver; Juan P Horcajada
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

9.  A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis.

Authors:  Sunish Shah; David P Nicolau; Dayna McManus; Jeffrey E Topal
Journal:  Open Forum Infect Dis       Date:  2021-05-12       Impact factor: 3.835

10.  Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.

Authors:  Katie Stokem; Jonathan B Zuckerman; David P Nicolau; Minkey Wungwattana; Edmund H Sears
Journal:  Respir Med Case Rep       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.